Enoximone 💊
Always check the BNF link here 📖 for the most up-to-date guidance.
⚙️ Mode of Action
- Enoximone is a phosphodiesterase-3 (PDE-3) inhibitor 💊.
- Increases intracellular cAMP in cardiac myocytes → enhanced calcium influx → positive inotropy (increased contractility).
- Also causes vasodilation by relaxing vascular smooth muscle → reduced preload and afterload.
💊 Indications & Dose
| Indication | Dose / Frequency | Route |
| Acute decompensated congestive cardiac failure (CCF) |
0.5–1 mg/kg IV (max infusion rate 12.5 mg/min), then 500 micrograms/kg every 30 min, titrated to response.
Maximum: 3 mg/kg over 3–6 h. |
IV |
⚠️ Reserved for short-term management of severe, refractory heart failure when standard therapy is insufficient.
⚠️ Interactions
- See BNF. May interact with other inotropes, vasodilators, and anti-arrhythmics.
🔎 Cautions
- Use only under specialist supervision with close monitoring (ECG, BP, renal function).
- Hypotension and arrhythmias are common risks ⚡.
🚫 Contraindications
- Avoid in hypertrophic obstructive cardiomyopathy (HOCM) or severe valve stenosis (risk of worsening obstruction).
❗ Side Effects
- Hypotension, tachyarrhythmias, chest pain ❤️.
- GI upset (nausea, vomiting, diarrhoea) 🤢.
- Thrombocytopenia (rare).
📚 References
📝 Revisions
- Added mechanism detail and clarified dosing/monitoring pearls.